🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

421 results for “Pari” Clear

  1. Talazoparib

    BioMarin Pharmaceutical Australia Pty Ltd

    Childhood Solid Tumors

    phase 1 small molecule completed

    1 trial

  2. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  3. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in treatment of uncomplicated lower urinary tract infections.

    Sciencepharma Sp. z o.o

    Not applicable (submitted trial is a bioequivalence in healthy subjects)

    phase 1 other active

    1 trial

  4. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment and prevention of Influenza.

    Lacuna Pharma Pty Ltd

    influenza

    phase 1 other active

    1 trial

  5. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adult patients.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  6. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adults patients.

    Lacuna Pharma Pty Ltd

    Bioequivalence study under fasting conditions

    phase 1 other active

    1 trial

  7. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of type 2 diabetes mellitus in adults and children aged 10 years and above, and heart failure and chronic kidney disease in adults patiens.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects.

    phase 1 other active

    1 trial

  8. To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents after single dose administration and to assess BE of a regular strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents at steady state in men with prostate cancer

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 1 other active

    1 trial

  9. olaparib

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  10. veliparib

    BRIGHT MINDS BIOSCIENCES INC.

    Small Cell Lung Cancer SCLC

    phase 1 small molecule active

    1 trial

  11. -, -, SULFAMETHOXAZOLE AND TRIMETHOPRIM

    Pari Pharma GmbH

    Pyelonephritis, Kidney Transplant recipients

    approved small molecule active

    1 trial

  12. AMOXICILLIN

    Pari Pharma GmbH

    Adults diagnosed with lower limbs erysipelas

    approved small molecule active

    1 trial

  13. AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFEPIME , CEFOTAXIME, SPIRAMYCIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

    Pari Pharma GmbH

    EA-COPD (with mechanical ventilation, invasive or non-invasive, or high-flow nasal oxygen therapy).

    approved small molecule active

    1 trial

  14. AMPICILLIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , OFLOXACIN , MOXIFLOXACIN , AZITHROMYCIN , LEVOFLOXACIN , AMOXICILLIN , PRISTINAMYCIN , ERYTHROMYCIN , CIPROFLOXACIN , CLARITHROMYCIN

    Pari Pharma GmbH

    Community acquired pneumonia (CAP)

    approved small molecule active

    1 trial

  15. BILINDA GYNIAL 0,03 mg/2 mg Filmtabletten, Selina Gynial 0,03 mg/0,15 mg Filmtabletten

    Pari Pharma GmbH

    Hormonal contraception

    approved small molecule active

    1 trial

  16. CEFAZOLIN

    Pari Pharma GmbH

    Infection prophylaxis

    approved small molecule active

    1 trial

  17. COBICISTAT , OLAPARIB

    Disc Medicine

    Cancer

    approved small molecule active

    1 trial

  18. DONEPEZIL, DONEPEZIL

    Pari Pharma GmbH

    Interest of adding donepezil to the non-medicinal care pathway recommended in France for Alzheimer's disease

    approved small molecule active

    1 trial

  19. Enema transplant of fecal microbiota, Placebo double encapsulated oral transplant of fecal microbiota, Placebo coloscopic transplant of Fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Crohn’s disease

    approved small molecule active

    1 trial

  20. Enoxaparin

    Sanofi Pasteur

    Acute Illness

    approved small molecule completed

    1 trial

  21. Enoxaparin 40 mg q12h

    United Therapeutics Europe Ltd

    Traumatic Injury

    approved small molecule completed

    1 trial

  22. Low-Molecular-Weight Heparins Calcium Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pneumonia

    approved small molecule completed

    1 trial

  23. MEROPENEM AND VABORBACTAM , LINEZOLID , TEDIZOLID , SULFAMETHOXAZOLE AND TRIMETHOPRIM , -, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , -, DAPTOMYCIN , -, COLISTIN , -, METRONIDAZOLE , AMIKACIN , IMIPENEM, CILASTATIN AND RELEBACTAM

    Pari Pharma GmbH

    Pyogenic liver abscess

    approved small molecule active

    1 trial

  24. MUCODRILL 600 mg SANS SUCRE, comprimé effervescent édulcoré au sucralose, FOLINORAL 25 mg, gélule, VITAMINE B12 GERDA 250 microgrammes, comprimé sécable, Omacor 1000 mg capsules molles

    Pari Pharma GmbH

    Ultra High Risk of psychosis and first episode psychosis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources